|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-27
|
|
pubmed:abstractText |
JAK2(V617F) mutation has been recognized as a possible thrombotic risk factor in essential thrombocythaemia (ET). It's role is probably due to an increased myeloid proliferation and white blood cells (WBC) activation. Only few data are available about the effect of JAK2(V617F) on hemorrhagic risk. The aim of our study was to evaluate the influence of the mutational status on hemorrhagic complication.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-10673283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-12239137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-12893745,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-15003898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-15327515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-15781101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-15985544,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16007902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16197451,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16325696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16369984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16398659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16461300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-16484586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-17110452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-17229651,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-17464935,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20104275-18166784
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1723-2007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
21-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20104275-Adult,
pubmed-meshheading:20104275-Aged,
pubmed-meshheading:20104275-Aged, 80 and over,
pubmed-meshheading:20104275-Amino Acid Substitution,
pubmed-meshheading:20104275-Female,
pubmed-meshheading:20104275-GPI-Linked Proteins,
pubmed-meshheading:20104275-Hemorrhage,
pubmed-meshheading:20104275-Humans,
pubmed-meshheading:20104275-Isoantigens,
pubmed-meshheading:20104275-Janus Kinase 2,
pubmed-meshheading:20104275-Leukocyte Count,
pubmed-meshheading:20104275-Leukocytes,
pubmed-meshheading:20104275-Male,
pubmed-meshheading:20104275-Membrane Glycoproteins,
pubmed-meshheading:20104275-Middle Aged,
pubmed-meshheading:20104275-Mutation, Missense,
pubmed-meshheading:20104275-Receptors, Cell Surface,
pubmed-meshheading:20104275-Retrospective Studies,
pubmed-meshheading:20104275-Risk Factors,
pubmed-meshheading:20104275-Thrombocythemia, Essential,
pubmed-meshheading:20104275-Thrombosis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
|
|
pubmed:affiliation |
Dipartimento di Ematologia, Servizio di Prevenzione e Cura Sindromi Emorragiche e Trombotiche, Ospedale Civile dello Spirito Santo, Pescara, Italy. andreapatriarca80@gmail.com
|
|
pubmed:publicationType |
Journal Article
|
